Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver  by Matsuzaki, Yasushi et al.
Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis
in cholestatic hamster liver
Yasushi Matsuzaki a,*, Bernard Bouscarel b, Tadashi Ikegami a, Akira Honda a,c, Mikio Doy c,
Susan Ceryak b, Sugano Fukushima a, Shigemasa Yoshida a, Junichi Shoda a, Naomi Tanaka a
aDepartment of Gastroenterology and Hepatology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City,
305-8575 Ibaraki, Japan
bDepartment of Medicine, The George Washington University, Washington, DC, USA
cIbaraki Prefectural Institute of Public Health, Mito, Ibaraki, Japan
Received 18 April 2002; received in revised form 20 June 2002; accepted 20 June 2002
Abstract
The aim of this study was to explore the regulation of serum cholic acid (CA)/chenodeoxycholic acid (CDCA) ratio in cholestatic hamster
induced by ligation of the common bile duct for 48 h. The serum concentration of total bile acids and CA/CDCA ratio were significantly
elevated, and the serum proportion of unconjugated bile acids to total bile acids was reduced in the cholestatic hamster similar to that in
patients with obstructive jaundice. The hepatic CA/CDCA ratio increased from 3.6 to 11.0 (P < 0.05) along with a 2.9-fold elevation in CA
concentration (P< 0.05) while the CDCA level remained unchanged. The hepatic mRNA and protein level as well as microsomal activity of
the cholesterol 7a-hydroxylase, 7a-hydroxy-4-cholesten-3-one 12a-hydroxylase and 5h-cholestane-3a,7a,12a-triol 25-hydroxylase were
not significantly affected in cholestatic hamsters. In contrast, the mitochondrial activity and enzyme mass of the sterol 27-hydroxylase were
significantly reduced, while its mRNA levels remained normal in bile duct-ligated hamster. In conclusion, bile acid biosynthetic pathway via
mitochondrial sterol 27-hydroxylase was preferentially inhibited in bile duct-ligated hamsters. The suppression of CYP27A1 is, at least in
part, responsible for the relative decreased production of CDCA and increased CA/CDCA ratio in the liver, bile and serum of cholestatic
hamsters.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The total serum bile acid concentration increases in
patients with various hepatobiliary diseases: e.g., acute
and chronic hepatitis, liver cirrhosis and intra- and extra-
hepatic cholestasis [1–3]. However, the composition of
serum bile acids in patients with cholestasis is very different
from that in patients with other hepatobiliary diseases. In
cholestasis, the ratio of the serum concentration of the
primary bile acid cholic acid (CA), to chenodeoxycholic
acid (CDCA) increases to more than one [1–3], while the
proportion of unconjugated bile acids is reduced [2,3].
However, the mechanism(s) responsible for the altered bile
acid biosynthesis under cholestatic conditions remains
unknown.
Production of CA and CDCA from cholesterol is princi-
pally regulated by two key enzymes, namely microsomal
cholesterol 7a-hydroxylase (CYP7A1) and mitochondrial
sterol 27-hydroxylase (CYP27A1) [4]. CYP7A1 is the first
and rate-limiting enzyme in the classic pathway, while
CYP27A1 is the key enzyme in the alternative pathway as
depicted in Fig. 1. The microsomal 7a-hydroxy-4-cholesten-
3-one 12a-hydroxylase (CYP8B1) is an additional key
enzyme involved in bile acid biosynthesis [5]. This enzyme
is known to catalyze 12a-hydroxylation of 7a-hydroxy-4-
cholesten-3-one which is an intermediate in the classic path-
way. The role of CYP8B1 in the alternative pathway has not
been clarified, while it is believed that the alternative pathway
is mostly involved in CDCA synthesis [6]. However, recent
studies have suggested that 27-hydroxycholesterol could be
0925-4439/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0925 -4439 (02 )00157 -6
* Corresponding author. Tel.: +81-298-53-3138; fax: +81-298-53-3138.
E-mail address: ymatsuzaki-gi@umin.ac.jp (Y. Matsuzaki).
www.bba-direct.com
Biochimica et Biophysica Acta 1588 (2002) 139–148
Fig. 1. Bile acid biosynthesis from cholesterol initiated either by a series of ring modifications (classic pathway) or by side chain hydroxylation (alternative
pathway). Solid arrows represent known enzymatic steps while broken arrows represent putative reactions that have yet to be confirmed.
Y. Matsuzaki et al. / Biochimica et Biophysica Acta 1588 (2002) 139–148140
converted into CA [7,8] while 3h-hydroxy-5-cholestenoic
acid was not [7]. Thus, CA and CDCA are synthesized by
both pathways, and CYP8B1 appears to be the most impor-
tant enzyme regulating the ratio of CA to CDCA under
normal conditions [5,8].
In certain pathological conditions, however, CYP27A1
can also be important in determining CA/CDCA ratio.
Cerebrotendinous xanthomatosis (CTX) is a recessively
inherited disorder caused by mutations in CYP27A1 gene
located on human chromosome 2 [9–12]. In this disease,
the pool size of CDCA is markedly reduced while that of
CA is almost normal [13]. When CYP27A1 is defective,
not only 27-hydroxylation of cholesterol in the alternative
pathway but also 27-hydroxylation of 5h-cholestane-
3a,7a-diol and 5h-cholestane-3a,7a,12a-triol in the classic
pathway is blocked [14]. Therefore, in CTX, only the
microsomal 5h-cholestane-3a,7a,12a-triol 25-hydroxylase
(CYP3A) pathway is intact for side chain hydroxylation,
resulting in CA being the only bile acid synthesized [15,16]
(Fig. 1).
In the present study, we selected the cholestatic hamster
with the common bile duct ligated for 48 h as model. This
model was chosen since it has both the hepatic capacity for
cholesterol biosynthesis [17], as well as a bile acid compo-
sition [18] similar to that found in human. In this study, we
compared the bile acid concentration and composition in
serum, bile and liver tissue, as well as CYP7A1, CYP27A1,
CYP8B1 and CYP3A protein expression and activity in bile
duct-ligated and sham-operated hamsters. The results from
the present study showed that in the cholestatic hamster, the
increased serum CA/CDCA ratio was mainly due to the
reduced hepatic CDCA production probably derived, at least
in part, from the suppression of the mitochondrial
CYP27A1 protein expression and activity.
2. Materials and methods
2.1. Chemicals
7a-Hydroxycholesterol was obtained from Steraloids
(Wilton, NH). 27-Hydroxycholesterol was synthesized from
diosgenin [19] and purified by preparative thin-layer chro-
matography (TLC). 7a-Hydroxy-4-cholesten-3-one and
7a,12a-dihydroxy-4-cholesten-3-one were gifts from Dr.
T. Hoshita and Dr. K. Kihira (Pharmaceutical Institute,
Hiroshima University, Hiroshima, Japan). 5h-Cholestane-
3a,7a,12a-triol was prepared by electrolytic coupling of
cholic acid with isovaleric acid according to Bergstro¨m and
Krabisch [20]. 5h-Cholestane-3a,7a,12a,25-tetrol was syn-
thesized from CA by the method of Dayal et al. [21].
[25,26,26,26,27,27,27-2H7]cholesterol was obtained from
MSD Isotopes (Montreal, Canada). [2H7]7a-hydroxycholes-
terol and [2H7]27-hydroxycholesterol were prepared by
previously described methods [22,23]. [2,2,4,4-2H4]CA,
[2,2,4,4-2H4]DCA, and [2,2,4,4-
2H4]LCA were obtained
fromMSD Isotopes; [11,11,12,12-2H4]CDCA and [11,11,12,
12-2H4]UDCA were supplied by the Research Laboratories
of Nippon Kayaku Co. and Tokyo Tanabe Co. (Tokyo,
Japan), respectively. Leupeptin, phenylmethylsulfonyl fluo-
ride and soybean trypsin inhibitor were purchased from
Sigma Chemical Co. (St. Louis, MO). The human anti-
cholesterol 7a-hydroxylase antibody was a gift from Dr. T.
Tanabe (National Cardiovascular Disease Center, Osaka,
Japan). The rat anti-sterol 27-hydroxylase antibody was a
gift from Dr. D.W. Russell, University of Texas Southwestern
Medical Center, Dallas, TX.
2.2. Patients
We studied 20 human subjects. Eight had untreated
extrahepatic obstructive jaundice and the other 12 were
without hepatobiliary diseases. All patients provided written
informed consent and this study was conducted according
to the Declaration of Helsinki. Blood samples were
obtained in the morning before breakfast after overnight
fasting, and the plasma and/or serum was stored at  20 jC
until analysis.
2.3. Animals
Adult male Golden Syrian hamsters (100–130 g body
weight) were purchased from Harlan Sprague Dowley, fed a
standard rodent chow diet and maintained on a 12:12 h
light–dark cycle.
2.4. Surgical procedure
After fasting for 24 h, hamsters were anesthetized with
sodium nembutal (50 mg/kg body weight). The ligation of
the common bile duct was performed as previously described
[24]. Briefly, the abdomen was opened with a midline
incision, the common bile duct was dissected from the
surrounding tissue, and three ligations with silk thread were
performed. The bile duct was cut between the second and
third ligation from the gallbladder. Four hundred microliters
of antibiotic solution (300,000 U/ml) containing penicillin G
benzathine and penicillin G procaine (Durapen Vedco, Syr-
acuse, NY) were poured over the peritoneal cavity to avoid
infection. The incision of the abdominal wall was closed by
using separate sutures for the muscle layer and the skin.
Control hamsters underwent sham operation in which the
bile duct was not ligated. The hamsters were maintained
under fasting conditions for 24 h after surgery. Cholestasis
was suggested by the appearance of green urine and the
presence of an enlarged gallbladder. After 48 h, the animals
were sacrificed at noon and blood was collected by direct
puncture of the heart. Livers were then immediately frozen
and stored at  70 jC until used. Serum and gallbladder bile
were stored at  20 jC until analysis. All animals received
humane care in compliance with the George Washington
University guidelines.
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2.5. Bile acid analyses
2.5.1. Serum and biliary bile acids
Bile acid concentrations and profile in serum and
gallbladder bile were determined by high-performance
liquid chromatography (HPLC) combined with a 3a-
hydroxysteroid dehydrogenase-immobilized column ac-
cording to the method of Okuyama et al. [25]. Either
serum or bile was diluted with 100 mM potassium phos-
phate buffer (pH 7.2), and 5h-pregnane-3a,17a,20a-triol
was added as an internal standard. The mixture was
incubated at 64 jC for 30 min. Bile acids were then
extracted with a Bond Elut C18 cartridge (Varian, Harbor
City, CA). After evaporation, the residue was dissolved
in methanol, filtered through an Ultra-Free C3HV filter
(0.45 Am; Millipore, Bedford, MA), and analyzed by
HPLC.
2.5.2. Hepatic bile acids
Bile acid concentrations and profile in liver tissue were
determined by gas-chromatography mass-spectrometry
(GC-MS) according to our previously described method
[26]. Briefly, the liver specimen (10 mg wet weight) was
washed carefully with saline to remove biliary bile acids.
After addition of deuterium-labeled bile acids as internal
standards and solubilization in 5% NaOH at 80 jC for 30
min, bile acids were extracted by a Bond Elut C18 cartridge
and subjected to solvolysis and enzymatic hydrolysis. The
resulting deconjugated bile acids were converted into the
ethyl ester dimethylethylsilyl (DMES) ether derivatives and
quantified by high-resolution GC-MS with selected-ion
monitoring (SIM).
2.6. Assays for enzyme activities
2.6.1. CYP7A1 and CYP27A1 activities
Hepatic microsomes and mitochondria were prepared by
differential ultracentrifugation [27], and the protein deter-
mined according to the method of Lowry et al. [28]. The
activities of microsomal 7a-hydroxylation of cholesterol
and mitochondrial 27-hydroxylation of cholesterol were
measured by high-resolution GC-MS with SIM using
[2H7]7a-hydroxycholesterol and [
2H7]27-hydroxycholes-
terol as internal recovery standards [29].
2.6.2. CYP8B1 activity
Microsomal 12a-hydroxylase activity was assayed as
described by Noshiro et al. [30] with minor modifications.
Microsomes were incubated for 10 min at 37 jC with 7a-
hydroxy-4-cholesten-3-one (6 Ag dissolved in 5 Al of
isopropanol), NADPH (1 mM), and 100 mM potassium
phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a
total volume of 0.3 ml. The incubation was stopped by the
addition of 5 ml of benzene. The formation of 7a,12a-
dihydroxy-4-cholesten-3-one was quantified by HPLC
[30].
2.6.3. CYP3A activity
CYP3A activity was determined by assaying CYP3A
activity as described previously [31]. Microsomes were
incubated for 20 min at 37 jC with 5h-cholestane-
3a,7a,12a-triol (25 nmol dissolved in 10 Al of acetone),
NADPH (1.2 mM), glucose-6-phosphate (3.6 mM), 2 units
of glucose-6-phosphate dehydrogenase, and 100 mM potas-
sium phosphate buffer (pH 7.4) containing 0.1 mM EDTA
in a total volume of 0.5 ml. The reaction was stopped by
adding 2 ml of ethyl acetate. After the addition of 1 Ag of
5h-cholestane-3a,7a,12a,27-tetrol as an internal recovery
standard, tetrols were extracted twice with 2 ml of ethyl
acetate, purified by a Bond Elut SI cartridge, derivatized to
trimethylsilyl (TMS) ether and quantified by high-resolution
GC-MS with SIM.
2.7. Determination of CYP7A1 and CYP27A1 protein
expression level
Proteins from microsomal or mitochondrial fractions
(25–50 Ag) were separated by SDS-polyacrylamide gel
electrophoresis (PAGE) according to the procedure of
Laemmli [32]. After electrophoresis, the proteins were
transferred onto a polyvinylidine difluoride membrane
(Immobilon-P, Millipore). Transferred microsomal fraction
was probed with a rabbit anti-human CYP7A1 antibody
(1:1000) and transferred mitochondrial fraction was probed
with a rabbit anti-rat CYP27A1 antibody (1:1500), respec-
tively, followed by a donkey horseradish peroxidase-labeled
anti-rabbit immunoglobulin G (1:3000) (Amersham, Arling-
ton Heights, IL). The immunoreactive proteins were visual-
ized by enhanced chemiluminescence using a kit from
Amersham. After being exposed to the membrane, the
Hyperfilm (Amersham) was analyzed by densitometric
scanning.
2.8. Determination of steady-state mRNA levels of CYP7A1
and CYP27A1
Total RNA was obtained from the stored frozen liver
tissues by the method of Chomczynski and Sacchi [33] with
minor modifications using RNA-Zol B reagent (Tel-Test
Inc., TX). Complementary DNAs (cDNAs) were synthe-
sized from total RNA with M-MLV reverse transcriptase by
the random primer method. PCR was performed using 50
pmol of each primer, 200 ng of cDNA template, 1.25 units
of Taq DNA polymerase, 200 nmol/l deoxynucleoside
triphosphate, in the reaction buffer (10 mmol/l Tris–HCl,
pH 8.3, 50 mmol/l KCl, 1.5 mmol/l MgCl2, and 0.01%
gelatin) using a DNA thermal cycler (Gene-Amp PCR
system 2400; Perkin Elmer, Norwalk, CT). PCR was sub-
jected to the respective cycles (CYP7A1, 30; CYP27A1, 35;
and glyceraldehyde-3-phosphate dehydrogenase (G3PDH),
26) at 94, 55, and 72 jC for 1 min each, respectively. PCR
primers were designated by referring to cDNA sequences
for rat G3PDH, human, rat and rabbit CYP7A1, and human
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and rat CYP27A1. Primer designs were as follows: hamster
CYP7A1, sense 5V-CAC/TCT/CCA/TCT/TGA/GGA/CGG-
3V, antisense 5V-GTG/GCA/AAA/TTC/CCA/AGC/CTG-3V;
hamster CYP27A1, sense 5V-ACC/TTC/CTC/CCC/AAG/
TGG/AC-3V, antisense 5V-CAG/AAC/ACA/AAC/TGG/
GTG/TTC-3V; G3PDH, sense 5V-GAA/CGG/GAA/GCT/
CAC/TGG/CAT/GGC-3V, antisense 5V-CAG/CAA/CAG/
GGT/GGT/GGA/CCT/CA-3V. Aliquots of the reaction mix-
ture were electrophoresed on a 2% agarose gel. PCR
products were stained by SYBR-GREEN I (Molecular
Probe Inc., Eugene, OR) according to the manufacturer’s
instructions and semi-quantified using a multi-bioimager
(STORM, Molecular Dynamics Inc., Sunnyvale, CA). The
data were expressed relative to the amounts of G3PDH
mRNA present in each specimen.
2.9. Histological examination
Liver specimens from both sham-operated and 2-day bile
duct-ligated hamsters were fixed in 2% paraformaldehyde
and mounted. Specimens were evaluated both by light and
electron microscopy.
2.10. Statistical analysis
Data are reported as the meanF SD. The statistical
significance between the results in the different groups
was evaluated by the Student’s two-tailed t-test. For all
comparisons, significance was accepted at the level of
P < 0.05.
3. Results
Fig. 2 summarizes the data comparing the effects of
cholestasis on the serum bile acid concentration and com-
position in human vs. hamster. Serum total bile acid con-
centration was elevated 34-fold (P < 0.01) in patients with
obstructive jaundice while the elevation was 116-fold
(P < 0.01) in hamsters 48 h after bile duct ligation. CA/
CDCA ratio was increased from 0.30 to 1.54 (P < 0.01) in
patients and from 2.0 to 6.8 (P < 0.01) in hamsters. The pool
Table 1
Serum and biliary bile acid profile in sham-operated and bile duct-ligated
hamsters
Sham (n= 5) BDL (n= 5)
Serum (%) Bile (%) Serum (%) Bile (%)
CA
F 33F 17 0.3F 0.2 0.2F 0.0 0.8F 0.5
G 16F 8 33F 8 40F 1 38F 3
T 11F 9 37F 9 45F 2 41F 8
CDCA
F 17F 10 0.1F 0.1 < 0.1 < 0.1
G 5F 5 8F 4 4F 1 8F 3
T 8F 3 13F 5 9F 1 8F 1
DCA
F 9F 9 < 0.1 < 0.1 < 0.1
G 2F 2 3F 2 0.1F 0.0 2F 1
T < 0.1 4F 3 < 0.1 2F 1
LCA
F < 0.1 0.1F 0.0 < 0.1 < 0.1
G < 0.1 0.4F 0.2 < 0.1 < 0.1
T < 0.1 0.7F 0.5 < 0.1 < 0.1
UDCA
F < 0.1 < 0.1 0.9F 0.4 0.4F 0.4
G < 0.1 < 0.1 < 0.1 < 0.1
T < 0.1 < 0.1 0.7F 0.4 < 0.1
Total 100 100 100 100
Serum and bile were collected from hamsters 2 days after sham operation
(Sham) or bile duct ligation (BDL). F, Unconjugated bile acid; G, glycine-
conjugated bile acid; T, taurine-conjugated bile acid. Data are expressed as
meanF SD.
Fig. 2. Effects of cholestasis on total bile acid concentration (A), ratio of cholic to chenodeoxycholic acid concentration (B) and proportion of unconjugated to
total bile acid concentration (C) in human and hamster sera. Solid bars represent patients with extrahepatic obstructive jaundice (n= 8) or hamster 2 days after
bile duct ligation (n= 5), while open bars represent control humans (n= 12) or sham-operated hamsters (n= 5).
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of unconjugated bile acids was reduced from 29% to 5.2%
(P < 0.01) in patients and from 59% to 1.1% (P < 0.01) in
hamsters.
The respective serum and biliary bile acid compositions
in bile duct-ligated and sham-operated hamsters are shown
in Table 1. In sham-operated hamsters, the proportion of
serum unconjugated bile acids (59%) was significantly
greater than that in bile (0.5%). In contrast, these propor-
tions were rather similar (1.1% vs. 1.2%) in bile duct-ligated
hamsters. The ratios of glycine-conjugated to taurine-con-
jugated bile acids was not significantly different between
bile duct-ligated and sham-operated hamsters.
Table 2 reports the respective serum, hepatic and biliary
bile acid concentrations, as well as the CA/CDCA ratios in
the bile duct-ligated and sham-operated hamsters. After bile
duct ligation, in contrast to a markedly increased serum CA
and CDCA concentration, these bile acid concentrations
were significantly decreased in gallbladder bile. However,
the serum and bile CA/CDCA ratios were both significantly
elevated in bile duct-ligated hamsters. The highest CA/
CDCA ratio was observed in bile duct-ligated hamster liver
tissue. In this model, the hepatic CA concentration was
increased 2.9-fold (P < 0.05) while the other bile acid levels
were not significantly different from those in control liver.
Table 3 shows the activity of hepatic key enzymes
involved in bile acid biosynthesis. Microsomal CYP7A1,
CYP8B1 and CYP3A activities were similar in both bile
Table 2
Serum, hepatic and biliary bile acid concentrations in sham-operated and bile duct-ligated Hamsters
Sham BDL
Serum (n= 5) [AM] Liver (n= 4) [nmol/g] Bile (n= 5) [mM] Serum (n= 5) [AM] Liver (n= 4) [nmol/g] Bile (n= 5) [mM]
CA 2.4F 1.0 231F 236 94F 24 386F 12y 680F 227z 6.3F 1.0y
CDCA 1.2F 1.0 63F 57 29F 12 57F 10y 68F 26 1.3F 0.2y
DCA 0.4F 0.3 56F 50 10F 5 0.3F 0.2 82F 54 0.3F 0.2§
LCA <0.1a 7.8F 8.8 1.6F 0.7 < 0.1a 16F 13 < 0.01a,y
UDCA <0.1a 29F 27 0.04F 0.02 7.6F 3.6§ 18F 13 0.03F 0.02
Total 3.9F 2.5 387F 112 134F 14 452F 38y 864F 105y 7.9F 1.0y
CA/CDCA 2.0F 1.9 3.6F 1.4 2.8F 1.0 6.8F 1.4§ 11.0F 5.8z 5.0F 1.2z
Serum, liver and bile were collected from hamsters 2 days after sham operation (Sham) or bile duct ligation (BDL). Data are expressed as meanF SD.
y P < 0.001 vs. sham-operated hamsters.
z P < 0.05 vs. sham-operated hamsters.
§ P < 0.01 vs. sham-operated hamsters.
a Limit of detection.
Table 3
Hepatic activities of mitochondrial CYP27A1, and microsomal CYP7A1,
CYP8B1 and CYP3A in sham-operated, bile duct-ligated and cholestyr-
amine-treated hamsters
Enzymes Sham (n= 5) BDL (n= 5) CHY (n= 4)
pmol/min/mg protein
Mitochondrial
CYP27A1 1.7F 0.3 0.8F 0.3 * 1.7F 0.8
Microsomal
CYP7A1 1.6F 1.0 1.4F 0.6 4.7F 2.3y
CYP8B1 10F 6 11F 3 ND
CYP3A 38F 16 25F 12 ND
Livers were obtained from hamsters 2 days after either sham operation
(Sham), bile duct ligation (BDL) or fed a 4% cholestyramine containing
diet for 1 week (CHY). Specific activities of CYP27A1, CYP7A1, CYP8B1
and CYP3A were determined by measuring 27- and 7a-hydroxylations of
cholesterol, 12a-hydroxylation of 7a-hydroxy-4-cholesten-3-one and 25-
hydroxylation of 5h-cholestane-3a,7a,12a-triol, respectively. Data are
expressed as meanF SD.
ND, not determined.
* P < 0.005 vs. sham-operated hamsters.
y P < 0.05 vs. sham-operated hamsters.
Fig. 3. Western blot of hamster liver microsomal CYP7A1 and mito-
chondrial CYP27A1. S, sham-operated (n= 4); B, bile duct-ligated (n= 4);
C, cholestyramine-treated (n = 4). *, Percentage of sham operation.
yP< 0.001, compared to bile duct ligation, zP < 0.05, compared to sham
operation.
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duct-ligated and sham-operated hamsters. In contrast, the
mitochondrial activity of CYP27A1 was decreased by 53%
(P < 0.005) in the bile duct-ligated hamsters. In the present
study, we also used hamsters fed a diet containing 4%
cholestyramine known to activate hamster microsomal
CYP7A1 [34,35] as control (Table 3). The protein expres-
sion levels of CYP7A1 and CYP27A1 were determined by
Western blotting method using specific antibodies against
the human CYP7A1 and rat CYP27A1. As shown in Fig. 3,
CYP7A1 protein expression level did not change signifi-
cantly while that of CYP27A1 was significantly decreased
in the bile duct-ligated hamsters. This is in agreement with
the above reported results on these enzymes’ specific
activities. We also determined the steady-state mRNA
expression levels for CYP7A1 and CYP27A1 by semi-
quantitative RT-PCR (Fig. 4). However, bile duct ligation
for 2 days did not change the mRNA expression levels of
either of these two enzymes.
Histological examination suggested dilatation of the
hepatic ducts as well as increased biliary ductule prolifer-
ation in the bile duct-ligated hamster liver. This was
accompanied by infiltration of neutrophils and mononuclear
cells. However, neither hepatic necrosis nor periportal or
portal fibrosis was found. The electron microscopic findings
of liver sections 48 h after bile duct ligation were charac-
terized by swollen hepatocytes and a marked decreased or
complete disappearance of glycogen rosettes. The endoplas-
mic reticulum was dilated while the mitochondria showed
no significant pathological change in either form or number.
With respect to the canal of Hering, the epithelium showed
irregular nuclei in shape and size.
4. Discussion
Our cholestatic hamster model showed a significantly
increased serum CA/CDCA ratio and a markedly decreased
ratio of unconjugated to total bile acids, which are character-
istic features of patients with cholestatic liver diseases.
These results are different from those reported in the bile
duct-ligated rats. In the cholestatic rat model, the synthesis
of CA is either not changed [36] or decreased [37], whereas
the h-muricholic acid production is markedly enhanced
[36,38,39], and the CA/h-muricholic acid ratio reduced
[36,39]. Since h-muricholic acid is formed from CDCA
[39], CA/h-muricholic acid ratio in the rat relates to the CA/
CDCA ratio in human and hamster. The effect of bile duct
ligation on the total bile acid synthesis appears to be
different between rats and hamsters. In bile duct-ligated
rats, CYP7A1 activity was significantly up-regulated
[37,40,41], whereas CYP7A1 activity was not changed in
our hamster model. Similar results were also reported in
rhesus monkeys [42] and humans [43] where total bile acid
synthesis was suppressed during biliary obstruction. Thus,
there are considerable species-specific differences in bile
acid metabolism, and the hamster may be a better model
than the rat for studying bile acid metabolism relevant to
patients with obstructive jaundice.
Abnormal flow from hepatocyte canaliculi to sinusoids is
one of the important reasons for the increased level of serum
total bile acids. Actually, in bile duct-ligated hamsters, the
serum bile acid composition, including CA/CDCA ratio and
glycine- and taurine-conjugation pattern, were very similar
to that found in bile (Table 1). However, the elevated serum
CA/CDCA ratio in bile duct-ligated hamsters cannot be
Fig. 4. Relative amount of steady-state mRNA for CYP7A1, CYP27A1 and
G3PDH in the livers of sham-operated, bile duct-ligated and cholestyr-
amine-treated hamsters. S, sham-operated (n= 4); B, bile duct-ligated
(n= 4); C, cholestyramine-treated (n= 4). *, Ratio of mRNA expression
level between respective enzymes and G3PDH, percentage of sham
operation. yP < 0.001, compared to sham operation.
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solely explained by this abnormal back flow from bile or
hepatocytes to serum. The reason is that not only in serum
but also in the liver and bile, the CA/CDCA ratio was
significantly increased in the bile duct-ligated hamsters.
Therefore, altered bile acid synthesis in the cholestatic liver,
i.e. enhanced CA synthesis and/or decreased CDCA pro-
duction is strongly suggested.
When we measured the activity and protein expression
level of CYP7A1 and CYP27A1, two key enzymes in the
classic and alternative bile acid biosynthetic pathways,
respectively, CYP7A1 was not affected but CYP27A1 was
significantly down-regulated following bile duct ligation.
These results lend support to our hypothesis that in contrast
to the bile duct-ligated rats, the total bile acid synthesis was
not increased in the bile duct-ligated hamsters. A recent
report by Pandak et al. [8] demonstrated that CYP8B1 was
capable of 12a-hydroxylating bile acid intermediates from
both the classic and alternative pathways. In addition, these
authors described CYP8B1 to be the sole regulator of the
CA/CDCA ratio. However, as seen in CTX patients,
CYP27A1 is also an important enzyme in determining CA/
CDCA ratio under pathological conditions. In fact, decreased
CYP27A1 activity without change of CYP8B1 activity was
observed in bile duct-ligated hamsters and was associated
with an increased CA/CDCA ratio. Recent reports show that
induction of CYP3A family of genes is one of the important
mechanisms for detoxification of hydrophobic bile acids in
cholestasis [44,45]. The retained activity of CYP3A that is
also a key enzyme in the alternative side chain cleavage
pathway in CA biosynthesis [46] may explain why the
production of CAwas not reduced as much as that of CDCA
in the bile duct-ligated hamster model.
An interesting observation concerns the regulation of
CYP7A1 in cholestasis. In spite of a significantly increased
hepatic total bile acid concentration, CYP7A1 was not
down-regulated in the cholestatic liver. CDCA is a physio-
logical ligand for the farnesoid X receptor (FXR), an orphan
nuclear receptor [47–49]. The binding of CDCA to the
receptor leads to the repression of CYP7A1 gene tran-
scription. Our results showed that the hepatic CA concen-
tration was increased while that of CDCA remained
unchanged in the bile duct-ligated hamster, which is similar
to what is observed in the liver of patients with jaundice of
short duration [50]. This may be one of the reasons for the
lack of suppression of CYP7A1 activity and expression in
bile duct-ligated hamster, although another orphan nuclear
receptor, LXRa [51] may also play an important role in the
regulation of CYP7A1 in cholestasis.
In contrast to microsomal CYP7A1, CYP8B1 and
CYP3A enzymes, mitochondrial CYP27A1 activity and
protein level were significantly reduced in the liver of
cholestatic hamsters. Although the regulation of CYP27A1
has not yet been clarified, Segev et al. [52] recently reported
that the human CYP27A1 gene had a TATA-less promoter
and its transcription was initiated at a cluster of sites.
Dexamethasone up-regulates and cyclosporin A down-reg-
ulates CYP27A1 at the transcriptional level, while CA
inhibits CYP27A1 post-transcriptionally by affecting the
stability of its mRNA [52]. It is important to know that
there may be species-specific differences in the control of
CYP27A1 gene expression because in rat hepatocytes CA
repressed the transcription of CYP27A1 gene [53].
There are at least two hypotheses to explain the mech-
anism(s) of decreased CYP27A1 activity in bile duct-ligated
hamster. First, as shown in human [52] and rat [53],
CYP27A1 might be inhibited by an increased hepatic CA
concentration in cholestasis. Hamster hepatic CYP27A1
showed both reduced specific activity and protein expres-
sion level without decreased steady-state mRNA level,
suggesting CYP27A1 to be post-transcriptionally down-
regulated. In the rat extrahepatic cholestatic model, the
activity, protein and mRNA levels of the sodium-dependent
taurocholate cotransporting polypeptide (ntcp) were mark-
edly reduced [54]. In contrast, 6h-hydroxylations of CDCA
and LCA were significantly up-regulated and these hydro-
phobic bile acids were metabolized to less cytotoxic h-
muricholic acid [37,40]. Thus, in the rat model, a signal
seems to be generated under cholestatic conditions to
regulate bile acid uptake and synthesis, and to diminish
the accumulation of potentially hepatotoxic bile acids in
rats. Humans and hamsters do not synthesize h-muricholic
acid, but rather reduce the formation of CDCA by down-
regulating CYP27A1 as a protective mechanism, which
parallels the formation of h-muricholic acid in the rat.
Second, hydrophobic bile acids including CDCA are
known to cause cellular ATP depletion due to impairment
of mitochondrial function in rat hepatocytes [55]. Although
the hepatic concentration of bile acids other than CA were
not elevated in the cholestatic hamster model, that of CDCA
has been suggested to be transiently increased in the earlier
period after bile duct ligation. CDCA has also been shown
by us [24,56], as well as by others [57] to activate various
signal transduction pathways. It is therefore a possibility
that this bile acid can be responsible for the decreased
CYP27A1 protein expression and/or activity through its
regulation of signaling mechanisms. The role for a regu-
latory mechanism is supported by the fact that while the
glycogen rosettes were markedly decreased, there was no
significant pathological change in either mitochondrial
shape or number in the cholestatic hamster liver.
In summary, the hamster hepatic mitochondrial
CYP27A1 was post-transcriptionally down-regulated while
the microsomal CYP7A1 and CYP8B1 were not affected by
bile duct ligation. This could explain, at least in part, the
increased serum CA/CDCA ratio and the decreased CDCA
production observed in cholestatic hamsters.
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